The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Clinical and molecular characteristics of pulmonary sarcomatoid carcinoma

  • Sim, Jae Kyeom (Department of Internal Medicine, Korea University Guro Hospital) ;
  • Chung, Sang Mi (Department of Internal Medicine, Korea University Guro Hospital) ;
  • Choi, Jong Hyun (Department of Internal Medicine, Korea University Guro Hospital) ;
  • Oh, Jee Youn (Department of Internal Medicine, Korea University Guro Hospital) ;
  • Lee, Seung Heon (Department of Internal Medicine, Korea University Ansan Hospital) ;
  • Kim, Je Hyeong (Department of Internal Medicine, Korea University Ansan Hospital) ;
  • Min, Kyung Hoon (Department of Internal Medicine, Korea University Guro Hospital) ;
  • Hur, Gyu Young (Department of Internal Medicine, Korea University Guro Hospital) ;
  • Shim, Jae Jeong (Department of Internal Medicine, Korea University Guro Hospital) ;
  • Kang, Kyung Ho (Department of Internal Medicine, Korea University Guro Hospital) ;
  • Shin, Bong Kyung (Department of Pathology, Korea University Guro Hospital) ;
  • Lee, Ju Han (Department of Pathology, Korea University Ansan Hospital) ;
  • Lee, Sung Yong (Department of Internal Medicine, Korea University Guro Hospital)
  • Received : 2017.07.16
  • Accepted : 2017.08.25
  • Published : 2018.07.01
⟨ Previous Next ⟩

Abstract

Background/Aims: Pulmonary sarcomatoid carcinoma (PSC) is a poorly differentiated non-small cell lung cancer (NSCLC) that contains components of spindle or giant cells. Owing to its low prevalence, there are insufficient data regarding its clinical features, therapeutic strategies and prognosis. Methods: The medical records of 26 patients diagnosed with PSC from January 2009 to June 2015 were reviewed and analyzed for clinicopathological characteristics, treatment modality, and outcomes. Results: The median age was 69.5 years. Twenty-three patients (88%) were male. Twenty-four patients (92%) were smokers. The median time from symptom onset to diagnosis was one month. Eighteen patients (69%) were diagnosed at an advanced stage. Pleomorphic carcinoma was the most common subtype, and epidermal growth factor receptor (EGFR) mutation was positive in two of 11 patients. Among 13 patients tested for programmed death ligand 1 (PD-L1) immunohistochemistry assay, eight showed high expression of PD-L1. The median overall survival (OS) of all patients was 9.5 months. In total, 12 patients were treated with chemotherapy: nine with platinum-based doublet therapy, two with tyrosine kinase inhibitor, and one with docetaxel. Seven patients showed partial response or stable disease. The median OS and progression-free survival of patients who received chemotherapy were 8.7 and 2.8 months, respectively. Conclusions: PSC was more common in males, smokers, and the elderly, with worse prognosis than ordinary NSCLC; chemotherapy response was favorable, and EGFR mutation status and PD-L1 expression may offer more therapeutic options.

Keywords

References

  1. Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol 2015;10:1243-1260. https://doi.org/10.1097/JTO.0000000000000630
  2. Yendamuri S, Caty L, Pine M, et al. Outcomes of sarcomatoid carcinoma of the lung: a Surveillance, Epidemiology, and End Results Database analysis. Surgery 2012;152:397-402. https://doi.org/10.1016/j.surg.2012.05.007
  3. Park JS, Lee Y, Han J, et al. Clinicopathologic outcomes of curative resection for sarcomatoid carcinoma of the lung. Oncology 2011;81:206-213. https://doi.org/10.1159/000333095
  4. Vieira T, Girard N, Ung M, et al. Efficacy of first-line chemotherapy in patients with advanced lung sarcomatoid carcinoma. J Thorac Oncol 2013;8:1574-1577. https://doi.org/10.1097/01.JTO.0000437008.00554.90
  5. Pelosi G, Fraggetta F, Nappi O, et al. Pleomorphic carcinomas of the lung show a selective distribution of gene products involved in cell differentiation, cell cycle control, tumor growth, and tumor cell motility: a clinicopathologic and immunohistochemical study of 31 cases. Am J Surg Pathol 2003;27:1203-1215. https://doi.org/10.1097/00000478-200309000-00003
  6. Nakajima M, Kasai T, Hashimoto H, Iwata Y, Manabe H. Sarcomatoid carcinoma of the lung: a clinicopathologic study of 37 cases. Cancer 1999;86:608-616. https://doi.org/10.1002/(SICI)1097-0142(19990815)86:4<608::AID-CNCR9>3.0.CO;2-1
  7. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016;375:1823-1833. https://doi.org/10.1056/NEJMoa1606774
  8. Brooks DR, Austin JH, Heelan RT, et al. Influence of type of cigarette on peripheral versus central lung cancer. Cancer Epidemiol Biomarkers Prev 2005;14:576-581. https://doi.org/10.1158/1055-9965.EPI-04-0468
  9. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247. https://doi.org/10.1016/j.ejca.2008.10.026
  10. Roach C, Zhang N, Corigliano E, et al. Development of a companion diagnostic PD-L1 immunohistochemistry assay for pembrolizumab therapy in non-smallcell lung cancer. Appl Immunohistochem Mol Morphol 2016;24:392-397. https://doi.org/10.1097/PAI.0000000000000408
  11. Pelosi G, Sonzogni A, De Pas T, et al. Review article: pulmonary sarcomatoid carcinomas: a practical overview. Int J Surg Pathol 2010;18:103-120. https://doi.org/10.1177/1066896908330049
  12. Rossi G, Cavazza A, Sturm N, et al. Pulmonary carcinomas with pleomorphic, sarcomatoid, or sarcomatous elements: a clinicopathologic and immunohistochemical study of 75 cases. Am J Surg Pathol 2003;27:311-324. https://doi.org/10.1097/00000478-200303000-00004
  13. Fishback NF, Travis WD, Moran CA, Guinee DG Jr, Mc-Carthy WF, Koss MN. Pleomorphic (spindle/giant cell) carcinoma of the lung. A clinicopathologic correlation of 78 cases. Cancer 1994;73:2936-2945. https://doi.org/10.1002/1097-0142(19940615)73:12<2936::AID-CNCR2820731210>3.0.CO;2-U
  14. Koss MN, Hochholzer L, Frommelt RA. Carcinosarcomas of the lung: a clinicopathologic study of 66 patients. Am J Surg Pathol 1999;23:1514-1526. https://doi.org/10.1097/00000478-199912000-00009
  15. Martin LW, Correa AM, Ordonez NG, et al. Sarcomatoid carcinoma of the lung: a predictor of poor prognosis. Ann Thorac Surg 2007;84:973-980. https://doi.org/10.1016/j.athoracsur.2007.03.099
  16. Bae HM, Min HS, Lee SH, et al. Palliative chemotherapy for pulmonary pleomorphic carcinoma. Lung Cancer 2007;58:112-115. https://doi.org/10.1016/j.lungcan.2007.05.006
  17. Soo RA, Loh M, Mok TS, et al. Ethnic differences in survival outcome in patients with advanced stage non-small cell lung cancer: results of a meta-analysis of randomized controlled trials. J Thorac Oncol 2011;6:1030-1038. https://doi.org/10.1097/JTO.0b013e3182199c03
  18. Chang YL, Wu CT, Shih JY, Lee YC. EGFR and p53 status of pulmonary pleomorphic carcinoma: implications for EGFR tyrosine kinase inhibitors therapy of an aggressive lung malignancy. Ann Surg Oncol 2011;18:2952-2960. https://doi.org/10.1245/s10434-011-1621-7
  19. Tamura Y, Fujiwara Y, Yamamoto N, et al. Retrospective analysis of the efficacy of chemotherapy and molecular targeted therapy for advanced pulmonary pleomorphic carcinoma. BMC Res Notes 2015;8:800. https://doi.org/10.1186/s13104-015-1762-z
  20. Zou F, Xie G, Ma JA, Zhou DA, Jiang YI, Zheng JY. Epidermal growth factor receptor mutation heterogeneity analysis of pulmonary sarcomatoid carcinoma successfully treated with erlotinib: a case report. Oncol Lett 2015;9:2239-2243. https://doi.org/10.3892/ol.2015.3057
  21. Velcheti V, Rimm DL, Schalper KA. Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1). J Thorac Oncol 2013;8:803-805. https://doi.org/10.1097/JTO.0b013e318292be18
  22. Vieira T, Antoine M, Hamard C, et al. Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages. Lung Cancer 2016;98:51-58. https://doi.org/10.1016/j.lungcan.2016.05.013
  23. Kim S, Kim MY, Koh J, et al. Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: comparison of sarcomatous and carcinomatous areas. Eur J Cancer 2015;51:2698-2707. https://doi.org/10.1016/j.ejca.2015.08.013
  24. Shimoji M, Shimizu S, Sato K, et al. Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1). Lung Cancer 2016;98:69-75. https://doi.org/10.1016/j.lungcan.2016.04.021
  25. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372:2018-2028. https://doi.org/10.1056/NEJMoa1501824
  26. Dix Junqueira Pinto G, de Souza Viana L, Scapulatempo Neto C, Vicente Serrano S. Evaluation of PD-L1 expression in tumor tissue of patients with lung carcinoma and correlation with clinical and demographic data. J Immunol Res 2016;2016:9839685.

Cited by

  1. A Histologically Complete Response to Immunotherapy Using Pembrolizumab in a Patient with Giant Cell Carcinoma of the Lung: An Additional Report and Literature Review vol.2019, pp.None, 2019, https://doi.org/10.1155/2019/1763625
  2. 18F-FDG PET/CT imaging in pulmonary sarcomatoid carcinoma and correlation with clinical and genetic findings vol.33, pp.9, 2018, https://doi.org/10.1007/s12149-019-01374-5
  3. Pulmonary sarcomatoid carcinoma: progress, treatment and expectations vol.12, pp.None, 2018, https://doi.org/10.1177/1758835920950207
  4. Significant benefits of pembrolizumab in treating refractory advanced pulmonary sarcomatoid carcinoma: A case report vol.8, pp.13, 2018, https://doi.org/10.12998/wjcc.v8.i13.2876
  5. Clinicopathological and Prognostic Features of 67 Cases with Pulmonary Sarcomatoid Carcinoma: An 18-Year Single-Centre Experience vol.44, pp.11, 2018, https://doi.org/10.1159/000519454
  6. Genomic origin and intratumor heterogeneity revealed by sequencing on carcinomatous and sarcomatous components of pulmonary sarcomatoid carcinoma vol.40, pp.4, 2018, https://doi.org/10.1038/s41388-020-01573-9